Hepatitis B is the form of hepatitis that is not curable. An estimated 254 million people worldwide were living with chronic hepatitis B in 2022, and no available treatment can fully eliminate the virus from the body. Hepatitis D, which can only exist alongside hepatitis B, is also not curable. By contrast, hepatitis C is now curable in over 95% of cases, and hepatitis A and E almost always resolve on their own.
Why Hepatitis B Cannot Be Cured
The reason hepatitis B resists a cure comes down to how the virus hides inside liver cells. When the virus infects a cell, it deposits a special form of its DNA (called cccDNA) directly into the cell’s nucleus. This viral DNA sits there as a stable, self-sustaining template, continuously producing new copies of the virus. Even when antiviral drugs suppress the virus in the bloodstream to undetectable levels, those DNA reservoirs remain tucked inside the liver.
Making matters harder, liver cells are long-lived. They don’t turn over quickly the way skin or blood cells do, so the body has few natural opportunities to flush out infected cells. And the virus has a built-in backup system: new viral particles produced inside a cell can cycle back to the nucleus and replenish the DNA reservoir. This means the infection is essentially self-reinforcing at a cellular level, even under treatment.
How Hepatitis B Is Managed Instead
Because a true cure isn’t available, the goal of hepatitis B treatment is long-term viral suppression. Antiviral medications can keep the virus at very low levels in the blood, which reduces inflammation in the liver and lowers the risk of serious complications like cirrhosis and liver cancer. Not every person with chronic hepatitis B needs medication, though. Some people carry the virus in a relatively inactive state, and their doctors may recommend regular monitoring rather than immediate treatment.
For those who do take antivirals, treatment is often indefinite. Stopping medication can allow the virus to rebound because those DNA reservoirs in the liver are still intact. Regular liver cancer screening is also part of ongoing care, since chronic infection raises that risk even when the virus is well controlled.
What a “Functional Cure” Means
Researchers use the term “functional cure” to describe a realistic best-case outcome for hepatitis B. This doesn’t mean the virus is completely gone. It means the body’s surface marker for active infection (a protein called HBsAg) disappears from the blood and stays undetectable for at least six months, and viral DNA in the bloodstream drops below measurable levels. A person who achieves a functional cure can typically stop treatment without the virus rebounding.
The catch is that even in a functional cure, tiny amounts of viral DNA remain dormant in liver cells. The immune system keeps them in check, but the virus isn’t truly eradicated. Functional cures happen spontaneously in a small percentage of people each year, and they’re the target that most experimental therapies are aiming for.
New Approaches in Development
Dozens of experimental therapies are currently in clinical trials trying to achieve functional cures at higher rates. These fall into several broad categories. Some use small RNA molecules to intercept and destroy the virus’s genetic instructions before they can produce new viral proteins. Others block the virus from entering liver cells in the first place or interfere with the protein shell that protects viral DNA during replication.
Perhaps the most ambitious approach involves gene-editing tools designed to directly target and destroy or silence the viral DNA hiding in liver cell nuclei. These are still in early-stage trials. Another major strategy focuses on retraining the immune system, which hepatitis B is notoriously good at evading. Therapeutic vaccines, immune-activating compounds, and checkpoint inhibitors (similar to those used in cancer treatment) are all being tested to help the body’s own defenses recognize and clear infected cells. Most of these therapies are in Phase I or Phase II trials, meaning they’re years away from widespread availability if they prove effective.
Why Hepatitis D Is Also Not Curable
Hepatitis D is sometimes called a “satellite virus” because it cannot replicate on its own. It requires hepatitis B to survive. A person can only get hepatitis D if they are already infected with hepatitis B, either catching both at the same time or acquiring D after an existing B infection. This double infection tends to cause more severe liver disease than hepatitis B alone.
Treatment options for hepatitis D are limited. One prescription medication, an injectable form of interferon, can help some patients, but it doesn’t work for everyone and has significant side effects. People who develop end-stage liver disease from hepatitis D may ultimately need a liver transplant. Because hepatitis D depends on hepatitis B, widespread hepatitis B vaccination is the most effective way to prevent both infections.
Hepatitis C: Now Curable
Hepatitis C was once in the same category as hepatitis B, a chronic infection with no cure. That changed dramatically with the introduction of direct-acting antiviral medications. These oral drugs cure more than 95% of people with chronic hepatitis C in just 8 to 12 weeks of treatment. A person is considered cured when no viral genetic material is detectable in their blood 12 weeks after finishing treatment.
This is a true cure, not just suppression. The virus is eliminated from the body. The contrast with hepatitis B is striking: hepatitis C does not create the same kind of persistent DNA reservoir in liver cell nuclei, which is why drugs that block viral replication can actually clear it completely.
Hepatitis A and E: Typically Self-Limiting
Hepatitis A does not become a chronic infection. It causes an acute illness that can range from mild to severe, but the body clears the virus entirely. There is no “chronic hepatitis A,” and a vaccine is widely available for prevention.
Hepatitis E follows a similar pattern for most people, resolving without specific treatment. The one exception is in people with significantly weakened immune systems, particularly organ transplant recipients taking immunosuppressive drugs. In these patients, hepatitis E can rarely become a chronic infection. For the general population, though, hepatitis E is not a long-term concern.